TEVA
NYSETeva Pharmaceutical Industries Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$41.48-0.11 (-0.25%)
01:30 PM07:45 PM
News · 26 weeks97-48%
2026-04-192026-10-11
Mix4790d
- Other21(45%)
- SEC Filings10(21%)
- Insider9(19%)
- Earnings3(6%)
- Analyst3(6%)
- Leadership1(2%)
Latest news
25 items- PRTeva to Host R&D Day on Wednesday, November 11 in New York CityTEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva’s ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. Due to limited capacity, in-person attendance is by invitation only. Analysts and institutional investors invited to
- PRTeva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with SchizophreniaWELTRUZA™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring requiredThe approval is based on results from the pivotal Phase 3 SOLARIS trial, which demonstrated overall symptom improvement, significant reduction in illness severity and improvement in personal and social functioning, with a systemic safety profile consistent with oral olanzapine1As Teva drives forward its Pivot to Growth strategy, the company continues to deliver on its commitment to patient-cente
- INSIDERSEC Form 3 filed by Teva Pharmaceutical Industries Limited3 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric PatientsThe published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that ecopipam reduces tic severity, provides sustained benefit over time and helps prevent relapse without some of the complications associated with antipsychotic agents.¹Ecopipam is an investigational, selective D1 (dopamine) receptor antagonist targeting dopaminergic signaling in the brain’s direct motor pathway implicated in Tourette syndrome.Unlike D2 antipsychotics that target D2 receptors in the indirect pathway, ecopipam selectively targets D1 receptors in the direct motor pathway, offering a differ
- PRTeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette SyndromeBased on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipamAn interim 18-month analysis of an ongoing open-label extension study demonstrated a mean reduction in tic severity scores (45.6%) with no new safety signals observedAdditional analyses found that common concurrent psychiatric conditions did not negatively impact ecopipam’s efficacy or safety, adding to the growing body of evidence supporting ecopipam’s application currently under FDA Priority Review PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:
- ANALYSTTD Cowen initiated coverage on Teva Pharma with a new price targetTD Cowen initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $55.00
- PRTAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitivenessTEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that combines a broad API portfolio, deep scientific and technical capabilities, and an extensive global operations network serving customers worldwide. "I am honored to join TAPI at such an important moment in its evolution," said Mr. Rogasik. "TAPI combines a unique set of capabilities, assets and talented people with a well-earned reputation as a trusted partner to customers worldwide. As the pharmaceutical industry increasingly focuses on supply chain resilience and geographic dive
- PRTeva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.FDA approval of DEGEVMA marks another milestone in Teva’s Pivot to Growth strategy, demonstrating our ability to bring high-quality, more affordable treatment options to patients across complex therapeutic categories.DEGEVMA is Teva’s second FDA-approved biosimilar in 2026 and, together with PONLIMSI™ (denosumab-adet), establishes Teva's comprehensive denosuma
- PRTeva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ETTEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be
- PRTeva Releases Q3 2026 Aide MemoireTEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the "Investors" page on its website. Q3 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of third quarter 2026 results, which are expected to be released on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independe
- ANALYSTOppenheimer initiated coverage on Teva Pharma with a new price targetOppenheimer initiated coverage of Teva Pharma with a rating of Outperform and set a new price target of $50.00
- INSIDERInterim Chief Legal Officer Savage Brian exercised 4,503 units of Ordinary Shares at a strike of $34.70 and sold $285,215 worth of Ordinary Shares (7,342 units at $38.85), decreasing direct ownership by 25% to 8,500 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Mignone Roberto sold $14,356,802 worth of Ordinary Shares (367,600 units at $39.06) (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRNew Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older PatientsNew data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD) in patients aged ≥55 yearsAcross all four patient profiles, AUSTEDO® (deutetrabenazine) was most closely related to the attributes most valued by healthcare providersThese findings from Teva detail specific healthcare provider preferences around tolerability and efficacy, while reinforcing the importance of treatment for TD PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEV
- PRTeva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare CostsNew findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost savingsThe breadth of clinical evidence presented highlights Teva’s ongoing commitment to evaluating how therapies perform in patients’ everyday lives to assist in improving routine care and reducing the burden of severe mental illness PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutica
- PRTeva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in AdultsIn a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-'749 for ≥ 6 months met criteria for remission Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-'749 from existing regimens Ahead of the Q4 FDA anticipated approval decision, the growing body of science around TEV-'749 demonstrates Teva’s commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchise PARSIPPANY, N.J., Sept. 18, 20
- SECTeva Pharmaceutical Industries Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- PRTeva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia CareLong-acting injectables (LAIs) offer an opportunity to improve adherence and potential outcomes for patients with schizophreniaLongActingImpact.com is a new resource center designed to support clinicians in having informed treatment conversations with those living with schizophreniaAs a leader in neuroscience, Teva is committed to supporting clinicians by providing evidence-based resources which could help improve schizophrenia care PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com, a new educational website for
- SECSEC Form 8-K filed by Teva Pharmaceutical Industries Limited8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- SECAmendment: SEC Form 8-A12B/A filed by Teva Pharmaceutical Industries Limited8-A12B/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- PRTemporal Raises $550 Million in Series E Round: NYSE Content UpdateNYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Sept. 14, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on September 14thTemporal boosts its valuation to $12.55 billion. The company says its annualized run rate has grown more than 200% year-over-year.Co-founder and CEO Samar Abbas will join NYSE Live to discuss how his company will deploy the fresh funding.The RTW Institute celebrates its official launch today.The think tank focu
- PRTeva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth StrategyPARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will begin trading today directly on the New York Stock Exchange (NYSE) completing the company’s planned transition from its American Depositary Shares (ADSs) program. Teva’s shares continue to trade under the same ticker symbol "TEVA" on both the NYSE and the Tel Aviv Stock Exchange (TASE). "Today marks another meaningful milestone in Teva’s transformation," said Richard Francis, President and CEO of Teva. "The trading of our ordinary shares on the NYSE is expected to broaden inves
- SECTeva Pharmaceutical Industries Limited filed SEC Form 8-K: Regulation FD Disclosure8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- SECSEC Form FWP filed by Teva Pharmaceutical Industries LimitedFWP - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
- PRTeva Announces Successful Pricing of $4.9 billion (Equivalent) Senior NotesTEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the "Notes"). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redemptions of certain existing notes as further set out below (the "Conditional Redemptions"), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, for general corporate purposes, including the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be
TEVA FAQ
6 questionsWhat does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology...Where does TEVA stock trade?
Teva Pharmaceutical Industries Limited (TEVA) is listed on NYSE.What sector and industry is TEVA in?
Teva Pharmaceutical Industries Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TEVA?
Teva Pharmaceutical Industries Limited has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-10-01. Recent price targets range from $2300.00 to $4500.00.What companies are similar to TEVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TEVA side-by-side with any of them on Quantisnow.How can I track TEVA on Quantisnow?
Quantisnow aggregates Teva Pharmaceutical Industries Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEVA to receive live email and push alerts on every new disclosure.